Population Bioequivalence (PBE) analysis for in-vitro studies [Regulatives / Guidelines]

posted by balakotu – India, 2019-05-22 09:41 (2030 d 05:07 ago) – Posting: # 20288
Views: 3,778

(edited on 2019-05-23 07:07)

Dear All,

any one help to below topic..............

Population Bioequivalence (PBE) analysis is required for in-vitro studies as per FDA guidance for few products like Iron Sucrose Injection, Ciclosporine Ophthalmic Emulsion, Azelastine Nasal spray etc.

For performing PBE analysis there are two statistical methods
1. One-sided PBE
2. Traditional PBE

Which method is most preferable out of the two methods?

If the study is meeting criteria as per one-sided PBE analysis & not meeting the criteria as per the traditional PBE analysis, whether that study will be accepted by regulatory?

Which is the better method for PBE analysis that regulatory will accept?

Thanks& Regards
Kotu.

Complete thread:

UA Flag
Activity
 Admin contact
23,336 posts in 4,902 threads, 1,665 registered users;
36 visitors (0 registered, 36 guests [including 9 identified bots]).
Forum time: 13:49 CET (Europe/Vienna)

I’m all in favor of the democratic principle
that one idiot is as good as one genius, but I draw the line
when someone takes the next step and concludes
that two idiots are better than one genius.    Leo Szilard

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5